1 The EIC Accelerator Project

EIC Accelerator Program: Overview and Funding Structure

The EIC Accelerator program is an initiative launched by the European Innovation Council (EIC) aimed at supporting innovative startups and small to medium-sized enterprises (SMEs) with high growth potential. This program is particularly focused on deep-tech and high-impact innovations that address significant societal challenges. The EIC Accelerator provides funding through a blended finance model that combines grants and equity investments to help companies scale their operations and bring groundbreaking technologies to market.

Funding Details

Purpose and Impact of the EIC Accelerator

The EIC Accelerator program serves multiple purposes in the European deep-tech and startup ecosystem. First and foremost, it aims to foster innovation by supporting projects that hold the potential to disrupt existing markets or create entirely new ones. By providing a combination of grant and equity funding, the program mitigates the financial risks associated with early-stage technology development, thus encouraging more entrepreneurs to embark on innovative ventures.

Moreover, the EIC Accelerator plays a pivotal role in helping companies scale by facilitating access to private sector funding. By demonstrating viability and potential for growth through the initial financial support, startups can attract additional investors, thereby enhancing their market position and operational capacity. The program's emphasis on high-impact innovations aligns with the European Union's broader goals of economic growth, job creation, and sustainable development.

Case Study: Nurami Medical Ltd and the Nurami Project

Company Overview

Nurami Medical Ltd, based in Israel, is a notable winner of the EIC Accelerator program. The company specializes in medical nanofiber technology aimed at addressing critical challenges in neurosurgery, particularly cerebrospinal fluid (CSF) leakage.

Project Details: Nurami

The project, aptly named Nurami, focuses on developing advanced medical nanofiber technology designed to prevent cerebrospinal fluid leakage during neurosurgical procedures. This leakage can lead to severe complications, including infection, and is a significant concern for neurosurgeons. The technology seeks to enhance surgical outcomes by providing a more effective sealing mechanism that minimizes the risks of CSF leaks.

Technology Basics and Background

The core innovation of the Nurami project lies in its use of nanofibers, which are ultra-fine fibers typically less than 100 nanometers in diameter. These fibers possess unique properties, such as a high surface area-to-volume ratio, which enhances their mechanical strength and surface interactions. In the context of neurosurgery, the nanofiber technology is designed to create a robust barrier against CSF leakage while promoting biocompatibility and integration with surrounding tissue.

The technology leverages advanced materials science, specifically in the manipulation of polymeric substances to create nanofibers that can be deployed during surgical procedures. By utilizing a minimally invasive approach, the Nurami technology not only aims to reduce the incidence of CSF leakage but also enhances patient recovery times and overall surgical safety.

Conclusion

The EIC Accelerator program, through its blended finance approach, plays a crucial role in supporting innovative projects like Nurami. By offering substantial grant and equity funding, the accelerator enables startups like Nurami Medical Ltd to develop and scale their cutting-edge technologies. The potential impact of the Nurami project on neurosurgery exemplifies the program's commitment to fostering groundbreaking innovations that address pressing medical challenges, ultimately benefiting both patients and healthcare providers.

2 The Funding Rounds

# Nurami Medical Ltd: Funding History and Financial Overview

Nurami Medical Ltd, an Israeli medical device company founded in 2014, has established itself as a pioneering developer of soft tissue repair solutions. The company has secured significant financing through various funding rounds, including the prestigious EIC Accelerator grant in 2024.

EIC Accelerator Funding

In July 2024, Nurami Medical was awarded blended financing from the European Innovation Council (EIC) Horizon Accelerator program, which included:

• A €2.5 million grant
• Additional equity investment (amount unspecified)

This funding was announced on July 16, 2024, following a rigorous evaluation process that selected Nurami from a competitive field of applicants. The EIC funding recognized Nurami's innovative technology and its potential to transform the soft tissue repair industry.

Complete Funding History

Nurami Medical has raised a total of approximately $43.37 million across multiple funding rounds:

Recent Financing (2025)

• Round: Unattributed - III
• Amount: $30 million
• Date: March 3, 2025
• Purpose: To expand operations, scale production, construct a commercial manufacturing facility, build research and development labs, and establish clean rooms for producing its FDA-approved product

EIC Accelerator Grant (2024)

• Round: Grant + Equity
• Amount: €2.5 million grant plus additional equity investment
• Date: July 2024
• Purpose: To advance the development of its second product, currently in pre-clinical trials

Series B (2020)

• Round: Series B
• Amount: $6 million
• Date: November 2, 2020
• Investors: Included Almeda Ventures

Early Funding (2016)

• Round: Unattributed
• Date: December 20, 2016
• Amount: Not specified

Investor Information

Nurami Medical has attracted investment from five known investors:

Company Valuation

The search results do not provide specific valuation figures for Nurami Medical across its funding rounds. Valuations are typically submitted by companies, mined from state filings or news, or based on comparable valuation models, but this information is not disclosed in the available sources.

Exit Events

As of May 2025, there are no reported exit events such as IPOs, buyouts, or acquisitions for Nurami Medical. The company remains privately held and continues to develop and commercialize its medical technology products.

Current Business Focus

Nurami Medical is utilizing its funding to support:

The company's technology leverages unique combinations of electrospun polymers and smart materials for soft tissue repair, specifically addressing cerebrospinal fluid leakage in neurological surgeries.

Sources: - Nurami Medical chosen for Blended Financing by the EIC

• Nurami Medical Awarded a €2.5 Million EIC Grant
• Nurami Medical Secures $30M
• Exclusive Financial Advisor to Nurami Medical Ltd
• Nurami Medical Stock Price, Funding, Valuation

3 The Press Releases

Nurami Medical's EIC Accelerator Achievement and Recent Developments Nurami Medical Ltd., an Israel-based medical device company specializing in soft tissue repair solutions, secured blended financing from the European Innovation Council (EIC) Accelerator program in March 2024, with results announced on July 15–17, 2024. The funding package includes a €2.5 million grant and additional equity investment to advance their electrospun polymer-based technologies.

Key Details from Press Releases and Updates

• Technology Focus: Nurami’s proprietary platform uses electrospun nanofibers and smart materials to create bio-surgical implants that address complications like post-surgical leaks while promoting tissue regeneration. Their inaugural product, ArtiFascia®, is already commercialized in the US for dura repair and awaits CE approval.
• Product Pipeline: The EIC funding will accelerate development of their second product, currently in pre-clinical trials.
• Leadership: Co-founded in 2014 by Dr. Amir Bahar (COO) and Nora Nseir Manassa (co-CEO), the company is co-led by Hannoch Marksheid (co-CEO).

No recent press releases regarding new partnerships, patents, or team changes beyond leadership details were identified. Social media updates or blog posts specific to their website were not referenced in available materials.

---

Sources
Nurami Medical Awarded a €2.5 Million EIC Grant
Nurami Medical chosen for Blended Financing by the EIC
Nurami awarded €2.5 million EIC grant
NURAMI MEDICAL LTD Company Profile
Nurami: Home

4 The Technology Advancements

Nurami Medical Ltd: Post-EIC Accelerator Funding Advancements

Since receiving €2.5 million in blended financing from the European Innovation Council (EIC) Accelerator in July 2024, Nurami Medical has accelerated development of its soft tissue repair technologies. While the EIC grant was awarded later than the March 13, 2024 date mentioned in your query (public records confirm July 16, 2024), below are their key advancements post-EIC funding:

Current Capabilities

Nurami specializes in nanofiber-based surgical implants, leveraging electrospun polymers to create biomimetic scaffolds for dura mater repair and other soft tissues. Their flagship product, ArtiFascia®, is FDA-cleared for defects up to 25 cm² and available commercially in the U.S., with CE approval pending. A second product, ArtiFix, combines a sealant patch and scaffold layer for cranial/spinal repair and is now in pre-clinical trials.

---

Post-EIC Funding Developments

• ArtiFix Development: The EIC funds are directed toward advancing ArtiFix, a bioabsorbable patch designed to prevent cerebrospinal fluid (CSF) leaks during neurosurgery. Pre-clinical trials are ongoing ahead of planned human trials.
• Manufacturing Scale-Up: The company is constructing commercial production facilities targeting annual outputs of ~40,000 units.

Commercialization Efforts: ArtiFascia® launched commercially in the U.S., while Nurami seeks regulatory approvals for EU markets. No customer pilots are explicitly reported post-July 2024, but existing FDA clearance implies active clinical use.

While no new peer-reviewed studies or whitepapers were disclosed publicly since mid-2024, Nurami’s technology received validation through competitive EIC selection criteria emphasizing breakthrough potential.

---

Intellectual Property & Collaborations

No new patents or scientific publications were announced post-EIC grant as of available data. However:

• Their core IP involves proprietary electrospinning methods for creating multifunctional nanofiber matrices mimicking natural extracellular structures.
• Collaborative efforts likely continue with EU partners under the EIC Horizon program’s framework.

---

Outlook

Nurami aims to address a $1 billion neurosurgical market by solving CSF leakage complications through ArtiFix’s suture-free design—a critical innovation reducing postoperative risks like infections. With expanded manufacturing capacity and ongoing trials, they position themselves as leaders next-generation soft tissue regeneration.

---

Sources Used:

Nurami Medical Awarded €2.5M EIC Grant PR Newswire Cordis Project Page Business of Bioprinting

5 The Partnerships and Customers

Nurami Medical Ltd. Partnerships and Strategic Positioning Post-EIC Accelerator Funding Following its €2.5 million EIC Accelerator grant in July 2024, Nurami Medical has focused on advancing its soft tissue repair technologies, though specific customer or partner names remain undisclosed in available materials. Key developments include:

• Financial Collaborations: Oppenheimer & Co. served as exclusive financial advisor for a $30 million financing round (February 2025), enabling commercialization of ArtiFascia® and clinical development of ArtiFix®, a cranial/spinal sealant patch.
• Product Commercialization: ArtiFascia®, FDA-cleared in 2024, is actively marketed in the U.S., with growing adoption among neurosurgeons addressing cerebrospinal fluid leaks.
• Manufacturing Expansion: The funding supports new facilities to scale production to 40,000 annual units, enhancing supply chain readiness for broader market penetration.

Market Positioning: Nurami’s technology targets the $1 billion neurosurgical repair market, with potential expansion into adjacent soft tissue applications. The EIC funding accelerates preclinical work on their second product, leveraging electrospun polymers and smart biomaterials to reduce surgical complications.

Technology Advancements: Partnerships with financial institutions like Oppenheimer provide capital to refine their nanofiber-based platforms, which mimic natural extracellular matrices to promote tissue regeneration. Scaling production capabilities ensures consistent quality for global regulatory submissions, including CE marking efforts for ArtiFascia®.

---

Sources

• Nurami Medical Awarded €2.5 Million EIC Grant
• Oppenheimer's Role in $30M Financing
• NASBS Exhibitor Profile

| Nurami's Manufacturing Expansion | Nurami Company Overview

6 The Hiring and Company Growth

Nurami Medical's Team Growth and Hiring Landscape Post-EIC Accelerator Funding As a 2024 EIC Accelerator winner, Nurami Medical Ltd, headquartered in Haifa, Israel, specializes in next-generation surgical products for soft tissue repair. While the company has not publicly disclosed specific headcount figures or recent hiring campaigns, its expansion is evident through the commercialization of its FDA-cleared ArtiFascia® patch—a multilayer graft designed for dural repair in neurosurgery.

The absence of explicit team size details suggests a focus on scaling operations through strategic partnerships and product development rather than large-scale recruitment. However, medical device companies at this stage typically prioritize roles in R&D, regulatory affairs, and sales to support market expansion. For Nurami, this likely means strengthening its technical and commercial teams to advance its electrospun nanofiber platform.

Key leadership remains anchored by CEO Hannoch Marksheid, with no reported changes to the founding team or management structure. The company’s growth trajectory appears tied to leveraging its proprietary biomaterials technology to address unmet needs in soft tissue repair markets globally. Future scaling efforts may involve targeted hires to accelerate clinical adoption and manufacturing scalability for ArtiFascia® and related products.

---

Sources

• Nurami: Home
• Nurami Medical - Startup Nation Finder
• Nurami company information - Startup Luxembourg
• Nurami Medical - French Tech Directory
• ArtiFascia - Nurami

7 The Media Features and Publications

Nurami Medical Ltd: A Pioneering Soft Tissue Repair Company

Nurami Medical Ltd, based in Haifa, Israel, has been at the forefront of innovative soft tissue repair technologies since its founding by Nora Nseir and Dr. Amir Bahar. The company's cutting-edge approach involves harnessing nanofibers and novel biomaterials to modernize soft tissue surgical repair. This technology aims to address complications associated with current soft tissue implants, such as dangerous leaks, and promote healthy tissue formation, including Dura repair.

Media Features and Publications

Nurami Medical has been featured in various publications and platforms, highlighting its groundbreaking work in medical technology. For instance, the company's participation in events and conferences, such as its appearance at the American Association of Neurological Surgeons (AANS) 2024, has been noted in industry news. Additionally, Nurami's acceptance into prestigious programs like the MedTech Innovator Program and the In-Ventech Growth Stage Program underscores its innovative stature in the medical sector.

Content and Interviews

Nora Nseir, co-founder and CTO of Nurami Medical, has presented the company's advancements in soft tissue repair technologies at conferences such as LSI Europe '23. Her presentations emphasize the company's use of nanofibers and biomaterials to improve patient recovery and address surgical challenges like cerebrospinal fluid leakages.

Conference and Fair Visits

Nurami Medical has actively participated in several conferences and events, leveraging these platforms to showcase its innovative products and technologies. Notably, the company's presence at AANS 2024 in Chicago highlighted its commitment to advancing neurosurgical solutions. Furthermore, Nurami's participation in the MedTech Innovator Program demonstrates its engagement with the broader medical innovation ecosystem.

Involvement in Events

The company's involvement in events is marked by its commitment to advancing soft tissue repair solutions. The successful completion of clinical trials and the launch of its flagship product, ArtiFascia, which received FDA clearance, are significant milestones in this journey. ArtiFascia is designed to address leaks following surgeries, a common concern in neurosurgery, and has been recognized for its potential to significantly improve patient outcomes.

EIC Accelerator Funding

On March 13, 2024, Nurami Medical Ltd was recognized as an EIC Accelerator winner, marking a significant milestone in its growth and development. This funding support is expected to further enhance the company's capabilities in developing advanced soft tissue repair technologies.

Sources: - Nurami Medical

• NURAMI MEDICAL LTD Company Profile
• Nurami Medical - Startup Nation Finder
• Nurami Medical - CB Insights
• News & Events - Nurami
• Nurami Medical finishes recruitment for tissue damage clinical trial
• About Us - Nurami
• Nora Nseir Presents Nurami Medical at LSI Europe '23
• Nurami Medical Lightning Pitch